Navigation Links
Lupin Launches Additional Strengths of Generic Lotrel® Capsules
Date:7/6/2011

BALTIMORE, July 6, 2011 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration (US FDA) has granted final approval for its Amlodipine / Benazepril 5mg/40mg, and 10mg/40mg capsules.  Commercial shipments of the product have already commenced.  This approval completes the product line as the Company was granted final approval for Amlodipine / Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules in February 2010.  

Lupin's Amlodipine / Benazepril capsules are the AB-rated generic equivalent of Novartis' *Lotrel® capsules indicated for the treatment of hypertension.   Amlodipine / Benazepril 5mg/40mg, and 10mg/40mg capsules had annual sales of approximately $290 million for the twelve months ended March 2011, based on IMS Health sales data.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant market share in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition holding global leadership positions in the Anti-TB and Cephalosporins space.  

Today, Lupin is the 5th largest and fastest growing Top 5 generics player in the US (by prescriptions), the only Asian company to achieve that distinction.   The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 million and Rs. 8,626  million respectively.  Please visit http://www.lupinworld.com for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited.  Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release

*Lotrel® is a registered trademark of Novartis Corp.

For More Information:
Contact: Edith St-Hilaire
Director of Marketing
(410) 576-2000


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Announces Launch of Generic Levaquin® Tablets
2. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
3. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
4. Lupin Expands Branded Play
5. JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
6. Global Medical Imaging Launches Worlds First Ultrasound Maintenance App
7. UCB Launches Research Alliance with Harvard University
8. Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System
9. Hocoma Launches New Version of its Established Gait Training Device LokomatPro
10. American Pain Foundation Launches New Educational Campaign, "Explain Your Pain," to Help Hispanic Americans Better Understand Chronic Pain and Pain Management
11. ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... Georgia (PRWEB) , ... April 29, 2016 , ... On ... rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB ... Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School of ... Grand Prize of the 2016 Wharton Business Plan Competition —as well as ... Award, and the Committee Award for Most ‘Wow Factor,’ making them the first ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):